APS proprietary technology creates economic value across the entire spectrum of drug development. APS lead compounds have already been "discovered" thus eliminating the traditional costs associated with the discovery process – such as candidate selection and lead optimization.

APS has developed a strong Intellectual Property portfolio with 9 issued US patents that cover the lead molecules and their variants. APS also has an extensive international patent portfolio, protecting the molecules and the applications worldwide.

APS drug candidates can be extended to several indications including:

• Oral and GI Mucositis
• Proctitis
• Ulcerative Colitis
• Inflammatory Bowel Disease
• Pain Management

APS has R&D and pre-clinical programs in all of the above areas and we are constantly working to enhance our pipeline of proprietary products.